VYNE Therapeutics Inc.

NasdaqCM:VYNE Stock Report

Market Cap: US$34.8m

VYNE Therapeutics Management

Management criteria checks 2/4

VYNE Therapeutics' CEO is Dave Domzalski, appointed in Mar 2020, has a tenure of 4.83 years. total yearly compensation is $2.72M, comprised of 23.5% salary and 76.5% bonuses, including company stock and options. directly owns 3.23% of the company’s shares, worth $1.12M. The average tenure of the management team and the board of directors is 4.8 years and 3.8 years respectively.

Key information

Dave Domzalski

Chief executive officer

US$2.7m

Total compensation

CEO salary percentage23.5%
CEO tenure4.8yrs
CEO ownership3.2%
Management average tenure4.8yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Oct 09
We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation

Apr 27
Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

May 04
We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

Aug 12

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

Jul 02
Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Mar 19
VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Jan 13

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Dec 03
VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Aug 13
Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

VYNE Therapeutics: Terrible Depreciation Of Shareholder Value

Jun 30

Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt

Jun 07
Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Feb 17
Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

CEO Compensation Analysis

How has Dave Domzalski's remuneration changed compared to VYNE Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$34m

Jun 30 2024n/an/a

-US$28m

Mar 31 2024n/an/a

-US$29m

Dec 31 2023US$3mUS$638k

-US$28m

Sep 30 2023n/an/a

-US$29m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$1mUS$638k

-US$34m

Sep 30 2022n/an/a

-US$35m

Jun 30 2022n/an/a

-US$40m

Mar 31 2022n/an/a

-US$42m

Dec 31 2021US$5mUS$638k

-US$44m

Sep 30 2021n/an/a

-US$59m

Jun 30 2021n/an/a

-US$69m

Mar 31 2021n/an/a

-US$226m

Dec 31 2020US$3mUS$501k

-US$256m

Sep 30 2020n/an/a

-US$270m

Jun 30 2020n/an/a

-US$269m

Mar 31 2020n/an/a

-US$120m

Dec 31 2019n/an/a

-US$95m

Sep 30 2019n/an/a

-US$71m

Jun 30 2019n/an/a

-US$64m

Mar 31 2019n/an/a

-US$63m

Dec 31 2018US$1mUS$440k

-US$74m

Compensation vs Market: Dave's total compensation ($USD2.72M) is above average for companies of similar size in the US market ($USD640.07K).

Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.

CEO

Dave Domzalski (57 yo)

4.8yrs

Tenure

US$2,716,350

Compensation

Mr. David T. Domzalski, also known as Dave, has been President, Chief Executive Officer and Director at VYNE Therapeutics Inc. (formerly known as Menlo Therapeutics Inc.). since March 9, 2020. Mr. Domzalsk...

Leadership Team

NamePositionTenureCompensationOwnership
David Domzalski
CEO, President & Director4.8yrsUS$2.72m3.23%
$ 1.1m
Iain Stuart
Chief Scientific Officer4.8yrsUS$1.16m0.87%
$ 303.6k
Mutya Harsch
General Counsel4.8yrsUS$1.13m0.98%
$ 340.6k
Tyler Zeronda
CFO & Treasurer3.6yrsno data0.86%
$ 299.5k
Subhashis Banerjee
Senior Vice President of Clinical Developmentless than a yearno datano data
Darrell Rigel
Consultant6.2yrsUS$115.20kno data

4.8yrs

Average Tenure

51yo

Average Age

Experienced Management: VYNE's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Domzalski
CEO, President & Director4.8yrsUS$2.72m3.23%
$ 1.1m
Sharon Surrey-Barbari
Independent Non Employee Director4.8yrsUS$116.10k0.0071%
$ 2.5k
Patrick LePore
Lead Independent Director4.3yrsUS$123.60k0.35%
$ 121.5k
Steven Basta
Director9.3yrsUS$83.60k0.051%
$ 17.6k
Anthony Bruno
Independent Non-Employee Director4.8yrsUS$101.10k0.013%
$ 4.4k
Elisabeth Sandoval-Little
Independent Director5.8yrsUS$108.60k0%
$ 0
Christine Borowski
Independent Director1yrno data0%
$ 0
Roy Fleischmann
Member of Scientific Advisory Board3.3yrsno datano data
Martin Okun
Member of Scientific Advisory Board3.3yrsno datano data
David Sachar
Member of Scientific Advisory Board3.3yrsno datano data
Olaf Stuve
Member of Scientific Advisory Board3.3yrsno datano data
Johnathan Whetstine
Member of Scientific Advisory Board3.3yrsno datano data

3.8yrs

Average Tenure

62yo

Average Age

Experienced Board: VYNE's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 02:53
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

VYNE Therapeutics Inc. is covered by 12 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas TsaoBarclays
Jason Matthew GerberryBofA Global Research
Julian HarrisonBTIG